NYSE$A
Agilent Technologies Inc · Q4 2025 earnings
Q4 2025 earnings · · After market close · Investor relations
Briefing
Agilent Technologies, Inc. reported solid financial results for the fourth quarter and full fiscal year 2025, exceeding revenue guidance and initiating fiscal year 2026 guidance.
Agilent Technologies reported fourth-quarter fiscal year 2025 revenue of $1.86 billion, exceeding guidance and showing significant growth. GAAP net income was $434 million with EPS of $1.53, while non-GAAP net income reached $452 million with EPS of $1.59. The company also provided a positive outlook for fiscal year 2026.
- Fourth-quarter 2025 revenue was $1.86 billion, a 9.4% reported increase and 7.2% core growth year-over-year, exceeding revenue guidance.
- GAAP net income for Q4 2025 was $434 million, with diluted EPS of $1.53, up 25% from Q4 2024.
- Non-GAAP net income for Q4 2025 was $452 million, with diluted EPS of $1.59, up 9% from Q4 2024.
- The company initiated strong fiscal year 2026 guidance, expecting revenue between $7.3 billion and $7.4 billion, and non-GAAP EPS between $5.86 and $6.00.
Headline financials
Revenue & EPS history
Agilent · Revenue · Quarterly
$1.86B
Revenue by segment
Agilent · $404M total across 1 segment · Q4 2023
- Agilent CrossLab$404M+6.0%100.0%
Forward guidance
Agilent Technologies expects fiscal year 2026 revenue to be in the range of $7.3 billion to $7.4 billion, representing a growth of 5% to 7% reported and 4% to 6% core. Non-GAAP EPS is projected to be between $5.86 and $6.00. For the first quarter of fiscal year 2026, revenue is expected to be between $1.79 billion and $1.82 billion, with non-GAAP EPS between $1.35 and $1.38 per share.
Tailwinds
- Fiscal year 2026 revenue expected to grow 5% to 7% reported and 4% to 6% core.
- Fiscal year 2026 non-GAAP EPS expected in the range of $5.86 to $6.00.
- Fiscal first-quarter 2026 revenue guidance shows an increase of 6% to 8% reported and 4% to 6% core.
- Fiscal first-quarter 2026 non-GAAP EPS expected in the range of $1.35 to $1.38 per share.
- The company enters FY26 with confidence and momentum, uniquely positioned to lead in life-sciences and diagnostics.
Headwinds
- Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations.
- Unforeseen changes in customer businesses or demand for products/services could impact results.
- Currency market fluctuations could negatively affect financial performance.
- Risks related to the ability to realize expected savings from integration and restructuring activities.
- Ongoing competitive, pricing, and gross-margin pressures could impact profitability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2025
+0.7%
Avg return
Earnings day
+0.8%
Avg return
5 days after
+0.5%
Avg return
30 days after
71%
51 / 72 earnings
Positive
+9.5%
Q4 2023
Best reaction
-11.3%
Q2 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q1 2026 | +0.2% | -4.6% | -11.6% | |
| Q4 2025 | +4.0% | -0.1% | -9.9% | |
| Q3 2025 | +5.3% | +5.5% | +4.0% | |
| Q2 2025 | +2.1% | +1.7% | +7.5% | |
| Q1 2025 | -5.5% | -8.5% | -13.2% | |
| Q4 2024 | +0.4% | +3.1% | +1.7% | |
| Q3 2024 | +0.3% | +0.5% | +0.2% | |
| Q2 2024 | -11.3% | -11.3% | -12.5% | |
| Q1 2024 | +4.2% | +5.8% | +10.7% | |
| Q4 2023 | +9.5% | +11.9% | +22.1% | |
| Q3 2023 | -4.2% | -5.8% | -9.3% | |
| Q2 2023 | -6.3% | -6.7% | -8.1% | |
| Q1 2023 | -3.3% | +1.2% | -5.4% | |
| Q4 2022 | +7.3% | +7.4% | +2.7% | |
| Q3 2022 | +6.3% | +2.8% | -0.6% | |
| Q2 2022 | -4.4% | +3.6% | -5.9% | |
| Q1 2022 | -4.6% | +1.3% | +3.3% | |
| Q4 2021 | -5.8% | -7.4% | -4.6% | |
| Q3 2021 | +0.6% | +3.7% | +6.9% | |
| Q2 2021 | -0.0% | +3.6% | +10.0% | |
| Q1 2021 | +1.7% | -0.9% | -4.2% | |
| Q4 2020 | +3.4% | +2.9% | +5.8% | |
| Q3 2020 | +0.5% | +0.8% | +2.1% | |
| Q2 2020 | +4.0% | +5.4% | +8.6% | |
| Q1 2020 | -0.5% | -0.9% | -23.4% | |
| Q4 2019 | +2.3% | +2.1% | +7.8% | |
| Q3 2019 | +2.9% | +6.1% | +15.2% | |
| Q2 2019 | -8.4% | -6.4% | -4.8% | |
| Q1 2019 | +0.5% | +2.3% | +1.9% | |
| Q4 2018 | +3.9% | +5.0% | +2.8% | |
| Q3 2018 | -1.8% | -1.9% | +5.1% | |
| Q2 2018 | -10.0% | -7.4% | -4.6% | |
| Q1 2018 | +5.4% | +5.3% | +2.3% | |
| Q4 2017 | +1.6% | +0.8% | -2.0% | |
| Q3 2017 | +4.2% | +2.7% | +10.2% | |
| Q2 2017 | +4.5% | +6.0% | +6.5% | |
| Q1 2017 | +2.2% | +2.2% | +5.0% | |
| Q4 2016 | +1.9% | -0.6% | +2.7% | |
| Q3 2016 | -3.2% | -1.4% | -7.2% | |
| Q2 2016 | +4.2% | — | — | |
| Q1 2016 | +4.6% | — | — | |
| Q4 2015 | +4.4% | — | — | |
| Q3 2015 | +1.0% | — | — | |
| Q2 2015 | +0.8% | — | — | |
| Q1 2015 | +3.5% | — | — | |
| Q4 2014 | -1.9% | — | — | |
| Q3 2014 | +5.1% | — | — | |
| Q2 2014 | -4.1% | — | — | |
| Q1 2014 | -7.8% | — | — | |
| Q4 2013 | +7.3% | — | — | |
| Q3 2013 | +0.1% | — | — | |
| Q2 2013 | +6.1% | — | — | |
| Q1 2013 | -5.6% | — | — | |
| Q4 2012 | +1.3% | — | — | |
| Q3 2012 | -8.2% | — | — | |
| Q2 2012 | +1.0% | — | — | |
| Q1 2012 | +2.4% | — | — | |
| Q4 2011 | -0.7% | — | — | |
| Q3 2011 | +0.6% | — | — | |
| Q2 2011 | +1.5% | — | — | |
| Q1 2011 | +2.6% | — | — | |
| Q4 2010 | +0.7% | — | — | |
| Q3 2010 | +0.5% | — | — | |
| Q2 2010 | -1.6% | — | — | |
| Q1 2009 | +0.9% | — | — | |
| Q1 2010 | +3.9% | — | — | |
| Q4 2007 | +2.7% | — | — | |
| Q2 2009 | +2.7% | — | — | |
| Q4 2009 | +2.7% | — | — | |
| Q4 2008 | +3.5% | — | — | |
| Q3 2009 | +3.5% | — | — | |
| Q3 2008 | +3.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro